ATE438391T1 - Pharmazeutische zubereitungen von amyloid- hemmenden verbindungen - Google Patents

Pharmazeutische zubereitungen von amyloid- hemmenden verbindungen

Info

Publication number
ATE438391T1
ATE438391T1 AT04744039T AT04744039T ATE438391T1 AT E438391 T1 ATE438391 T1 AT E438391T1 AT 04744039 T AT04744039 T AT 04744039T AT 04744039 T AT04744039 T AT 04744039T AT E438391 T1 ATE438391 T1 AT E438391T1
Authority
AT
Austria
Prior art keywords
amyloid
pharmaceutical preparations
inhibiting compounds
methods
therapeutic formulations
Prior art date
Application number
AT04744039T
Other languages
English (en)
Inventor
Audley Legore
Denis Garceau
Original Assignee
Bellus Health Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellus Health Int Ltd filed Critical Bellus Health Int Ltd
Application granted granted Critical
Publication of ATE438391T1 publication Critical patent/ATE438391T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT04744039T 2003-06-23 2004-06-21 Pharmazeutische zubereitungen von amyloid- hemmenden verbindungen ATE438391T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48098403P 2003-06-23 2003-06-23
US51211603P 2003-10-17 2003-10-17
US10/871,549 US20050142191A1 (en) 2003-06-23 2004-06-18 Pharmaceutical formulations of amyloid inhibiting compounds
PCT/IB2004/002381 WO2004112762A2 (en) 2003-06-23 2004-06-21 Pharmaceutical formulations of amyloid inhibiting compounds

Publications (1)

Publication Number Publication Date
ATE438391T1 true ATE438391T1 (de) 2009-08-15

Family

ID=33545348

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04744039T ATE438391T1 (de) 2003-06-23 2004-06-21 Pharmazeutische zubereitungen von amyloid- hemmenden verbindungen

Country Status (18)

Country Link
US (2) US20050142191A1 (de)
EP (2) EP1635799B1 (de)
JP (1) JP4903561B2 (de)
CN (1) CN103550196A (de)
AT (1) ATE438391T1 (de)
AU (2) AU2004248995B2 (de)
BR (1) BRPI0411808A (de)
CA (1) CA2529268C (de)
DE (1) DE602004022408D1 (de)
DK (1) DK1635799T3 (de)
ES (1) ES2328818T3 (de)
IL (1) IL172193A0 (de)
MX (1) MXPA05013974A (de)
NZ (1) NZ544685A (de)
PL (1) PL1635799T3 (de)
PT (1) PT1635799E (de)
SI (1) SI1635799T1 (de)
WO (1) WO2004112762A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146143A0 (en) * 1999-04-28 2002-07-25 Univ Kingston Compositions and methods for treating amyloidosis
AU5994900A (en) * 1999-07-09 2001-01-30 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
AU2003292936A1 (en) * 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
CA2900876A1 (en) 2004-12-22 2006-08-17 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
CA2611586A1 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
US20070049638A1 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
KR101443573B1 (ko) 2006-10-12 2014-11-03 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
AU2007337806A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
WO2010040232A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
US9735792B2 (en) 2013-01-08 2017-08-15 Rambus Inc. Integrated circuit comprising circuitry to determine settings for an injection-locked oscillator
CN106170563A (zh) 2014-03-21 2016-11-30 爱尔真公司 用于治疗神经病症的方法
EP3347002B1 (de) 2015-09-10 2023-06-07 Alzheon, Inc. Behandlung von alzhimer krankheit bei einer bestimmten patientenpopulation
CN108623501B (zh) 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
US12042566B2 (en) 2017-05-17 2024-07-23 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
WO2023212289A1 (en) 2022-04-28 2023-11-02 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases
WO2024119183A1 (en) 2022-12-02 2024-06-06 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658966A (en) * 1969-09-15 1972-04-25 Kowa Co Methods of treating hypertension
US3920833A (en) * 1974-08-08 1975-11-18 Stanley Drug Products Inc Antifibrinolytic agents
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0119274B1 (de) 1982-09-08 1986-11-26 MITSUI TOATSU CHEMICALS, Inc. Verfahren zur herstellung von aminoalkylsulfonsäuren
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
JP2642198B2 (ja) * 1989-08-24 1997-08-20 元庸 村上 胃粘膜障害治療剤
US5164295A (en) 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
GB9117716D0 (en) 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
JPH06510760A (ja) 1991-08-27 1994-12-01 ジ・アップジョン・カンパニー 代謝障害および代謝の治療法
JP3666818B2 (ja) * 1993-03-29 2005-06-29 クイーンズ ユニバーシティ アット キングストン アミロイド症の治療法
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
DE69528583T2 (de) * 1994-04-22 2003-07-10 Yamanouchi Pharmaceutical Co., Ltd. Kolon-spezifisches arzneistofffreisetzungssystem
US5683718A (en) * 1995-04-04 1997-11-04 Time-Cap Labs, Inc. Enteric coated tablet with raised identification character and method of manufacture
WO1997009925A2 (en) * 1995-09-12 1997-03-20 The General Hospital Corporation Method for early detection of ovarian cancer
AU703540B2 (en) * 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
PT1054664E (pt) * 1998-02-11 2012-11-02 Bhi Ltd Partnership Método para modulação da ativação de macrófagos
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
EP1077690A1 (de) * 1998-05-15 2001-02-28 Neurochem, Inc. Verwendung von amyloid-inhibitoren zur regulierung des neuronalen zelltodes
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
IL146143A0 (en) * 1999-04-28 2002-07-25 Univ Kingston Compositions and methods for treating amyloidosis
AU5994900A (en) 1999-07-09 2001-01-30 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
EP1225880A2 (de) * 1999-11-04 2002-07-31 Andrx Corporation Verwendung von einem hgm coa-reduktase inhibitor zur behandlung von amyloid-beta-precursor störungen
KR20090016517A (ko) * 1999-12-23 2009-02-13 벨루스 헬스 (인터내셔널) 리미티드 대뇌 아밀로이드 혈관병증을 조절하는 화합물 및 방법
US6376557B1 (en) * 2000-03-16 2002-04-23 Chanda Bhuwalka Zaveri Methods for treating alopecia
FR2832928B1 (fr) * 2001-11-30 2004-02-06 Dermo Cosmologie Lab De Composition a base d'ester de diosgenine applicable par voie topique
EP1459764A4 (de) * 2001-12-26 2006-08-16 Takeda Pharmaceutical Mittel zur behandlung von leichten erkennungsstörungen
AU2003292936A1 (en) * 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050038000A1 (en) * 2003-06-23 2005-02-17 Xianqi Kong Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
KR101443573B1 (ko) 2006-10-12 2014-11-03 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클

Also Published As

Publication number Publication date
AU2010201299A1 (en) 2010-04-22
PL1635799T3 (pl) 2010-01-29
AU2004248995B2 (en) 2010-01-07
DE602004022408D1 (de) 2009-09-17
EP1635799A2 (de) 2006-03-22
US8835500B2 (en) 2014-09-16
US20090182056A1 (en) 2009-07-16
JP4903561B2 (ja) 2012-03-28
JP2007518672A (ja) 2007-07-12
CA2529268A1 (en) 2004-12-29
EP1635799B1 (de) 2009-08-05
ES2328818T3 (es) 2009-11-18
WO2004112762A2 (en) 2004-12-29
AU2004248995A1 (en) 2004-12-29
CA2529268C (en) 2013-10-29
CN103550196A (zh) 2014-02-05
EP2127648A1 (de) 2009-12-02
WO2004112762A3 (en) 2005-06-02
BRPI0411808A (pt) 2006-08-08
US20050142191A1 (en) 2005-06-30
DK1635799T3 (da) 2009-11-23
IL172193A0 (en) 2009-02-11
PT1635799E (pt) 2009-09-23
MXPA05013974A (es) 2006-03-09
NZ544685A (en) 2009-05-31
SI1635799T1 (sl) 2009-12-31

Similar Documents

Publication Publication Date Title
ATE438391T1 (de) Pharmazeutische zubereitungen von amyloid- hemmenden verbindungen
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
CY2014028I2 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
BRPI0519567A2 (pt) heterociclos tricÍclicos, sua fabricaÇço e uso como agentes farmacÊuticos
CY1110305T1 (el) Μεθοδοι για την προληψη και θεραπευτικη αντιμετωπιση της μεταστασης καρκινου και της οστικης απωλειας που συνδεεται με τη μετασταση καρκινου
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
ATE538794T1 (de) Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
ECSP066516A (es) Formulaciones farmacéuticas, procedimientos y pautas de dosificación para el tratamiento y prevención de síndromes coronarios agudos
HUP0401903A2 (hu) Az ET-743 továbbfejlesztett alkalmazása daganatok kezelésére
BRPI0515885A (pt) derivados de ftalazinona, sua preparação e uso como agentes farmacêuticos
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
WO2007069073A3 (en) Pharmaceutical formulations of amyloid inhibiting compounds
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
ATE410148T1 (de) Pharmazeutische zubereitung zur oralen verwendung von heparin und seinen derivaten
DE60216457D1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
SE0004827D0 (sv) Therapeutic compounds
TH77759A (de)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1635799

Country of ref document: EP